Todd Druley

Chief Scientific Officer for Hematology, Danaher Corporation

Todd Druley completed his MD, PhD in 2002 at the University of Illinois. During his graduate studies, he was captivated by the Human Genome Project and the dawn of the genomics era. He pursued pediatric hematology/oncology at Washington University in St. Louis, which was one of three centers advancing genomics and the first to sequence the entire genome of an adult cancer patient. This opened an avenue as a physician-scientist bringing novel genomic methodologies to pediatric cancer care. From 2002 – 2021, Druley’s translational genomic laboratory developed novel computational methods and patented novel sequencing strategies to improve the sensitivity of genomic sequencing. This led to NIH-funded work making seminal observations in clonal hematopoiesis, clonal profiling of cancer, epidemiology of germline and somatic variation in various diseases. To date, his work consists of approximately 70 publications and nearly 7,000 citations. Druley established the Midwest’s first Pediatric Cancer Predisposition Program for children and families with germline mutations increasing their risk of cancer. He published national guidelines for the surveillance of children with overgrowth syndromes and documented previously unknown hearing defects in children with Beckwith-Weidemann Syndrome. Cumulatively, this body of work earned Druley induction into the American Society of Clinical Investigation in 2019.

That same year, he was offered the opportunity to become the first Chief Medical Officer (CMO) for ArcherDx, a clinical diagnostics tools company based in Boulder, CO. He built an international clinical and regulatory program consisting of more than 20 individuals focused on medical writing, regulatory applications and identifying translational opportunities to highlight the power of Archer’s anchored-multiplex PCR technology. After Archer’s sale to Invitae, Druley looked for the next phase of cancer diagnostics and identified single cell DNA and protein multi-omics as a tool that could couple the growing portfolio of precision medicines to a patient’s unique clonal cancer profile. He joined Mission Bio as their first CMO in 2022 and helped build diagnostic tools for AML and myeloma. He is currently the Chief Scientific Officer for Hematology at Danaher Diagnostics, an international conglomerate of diagnostic companies, where his role is to drive the development, deployment, utilization and regulatory approvals for new diagnostic tools in blood diseases and blood cancers.
In sum, Druley’s entire career has focused on translational cancer research and its application to improve patient outcomes as a physician, a scientist, and a biotech executive.